RxDoctor Payments Data

Edward Case

Psychiatry · Patton, CANPI 1407808785

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (52.8%), speaking fees and education — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by AbbVie at 45.8% of the total. 2025 is the largest year on record at $6,634, 7.7 times the $859 reported in 2019. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,706in general payments, 2019–2025

Across 536 payments — averaging $27.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$7K
  • Corium, LLC$2K
  • Otsuka America Pharmaceutical, Inc.$761
  • Teva Pharmaceuticals USA, Inc.$757
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$749
  • Sunovion Pharmaceuticals Inc.$651
  • plus $3K from 13 others

What the payments were for

  • Consulting fees$3602%
  • Speaking & faculty fees$6,18042%
  • Food & beverage$7,76753%
  • Education$3983%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,706 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California →

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl19$28,803
RexultiBrexpiprazole17$25,064
BelsomraSuvorexant46$22,013
Asenapine Maleate11$4,448
Desvenlafaxine Succinate ErDesvenlafaxine Succinate57$1,719
Buspirone Hcl57$878
Prazosin Hcl19$740
Olanzapine19$697
Duloxetine Hcl31$625
Quetiapine Fumarate35$564
Propranolol Hcl ErPropranolol Hcl17$539
Gabapentin50$508
Clonazepam45$432
Venlafaxine Hcl ErVenlafaxine Hcl30$393
Lamotrigine21$392

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$6,728$28,80319 claims
Otsuka America Pharmaceutical, Inc.Rexulti$761$25,06417 claims
MerckBelsomra$14$22,01346 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Patton

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →